Free Trial
NASDAQ:GILD

Gilead Sciences (GILD) Stock Price, News & Analysis

$67.55
+0.86 (+1.29%)
(As of 07/8/2024 ET)
Today's Range
$67.04
$68.18
50-Day Range
$63.15
$70.73
52-Week Range
$62.07
$87.86
Volume
5.75 million shs
Average Volume
8.59 million shs
Market Capitalization
$84.16 billion
P/E Ratio
187.64
Dividend Yield
4.56%
Price Target
$84.00

Gilead Sciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.37 Rating Score
Upside/​Downside
24.4% Upside
$84.00 Price Target
Short Interest
Healthy
1.52% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.98mentions of Gilead Sciences in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$137,260 Sold Last Quarter
Proj. Earnings Growth
93.07%
From $3.75 to $7.24 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.96 out of 5 stars

Medical Sector

16th out of 876 stocks

Biological Products, Except Diagnostic Industry

2nd out of 149 stocks

GILD stock logo

About Gilead Sciences Stock (NASDAQ:GILD)

Gilead Sciences, Inc. is a leading biopharmaceutical company in Foster City, California. Founded in 1987, the company's mission is to develop innovative medicines that address unmet medical needs and improve the lives of people around the world. Gilead focuses on discovering, developing, and commercializing therapies in HIV/AIDS, liver diseases, oncology, inflammatory and respiratory diseases, and cardiovascular conditions. 

Gilead's portfolio includes a wide range of products and therapies, with its most notable product being Truvada, a leading medication for HIV prevention. The company also offers other HIV treatments, such as Biktarvy and Descovy. In addition to its HIV franchise, Gilead has significantly advanced in treating chronic hepatitis B and C with drugs like Veklury and Epclusa. Furthermore, the company has expanded into oncology with therapies such as Trodelvy and Yescarta.

Gilead Sciences is led by experienced executives who bring industry knowledge and expertise. The company's Chief Executive Officer, Daniel O'Day, joined Gilead in 2019 and has a proven track record in the pharmaceutical industry. O'Day previously served as the CEO of Roche Pharmaceuticals, where he successfully led the company through significant growth.

Gilead Sciences has consistently delivered a solid financial performance in recent years. The company has reported strong revenue and net income numbers yearly. This growth was primarily driven by solid sales of Gilead's HIV and liver disease therapies. The company averages a profit margin between 25% - 30%. Gilead has maintained a healthy balance sheet with manageable levels of debt. Gilead's strong financial position allows it to invest in research and development initiatives and pursue strategic acquisitions to drive future growth.

Investor sentiment towards Gilead has improved in recent years due to the company's strong financial performance and promising pipeline of innovative therapies. The successful launch of new products, such as Trodelvy and Biktarvy, has further bolstered investor confidence in Gilead's growth prospects.

Gilead Sciences operates in the highly competitive biopharmaceutical industry, characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The industry is subject to evolving market dynamics, including changing reimbursement policies, patent expirations, and intense competition from established and emerging biotech firms.

Gilead's expansion into oncology has been promising, with the introduction of therapies targeting specific types of cancer. However, the oncology market is highly competitive, with several significant players and emerging biotechs vying for market share. Gilead's success in this area will depend on its ability to differentiate its products, demonstrate clinical efficacy, and navigate the evolving treatment landscape.

Gilead Sciences has identified several growth opportunities that can contribute to its future success. One key focus is expanding its product portfolio through internal research and development efforts and strategic acquisitions and partnerships. By investing in innovative therapies, Gilead aims to address unmet medical needs and strengthen its competitive position.

The company's pipeline includes potential breakthrough treatments for various diseases, including novel antiviral agents, immunology candidates, and cell therapies. Gilead also explores combination therapies to enhance treatment outcomes and extend its market reach. These advancements provide opportunities for revenue growth and market expansion.

Gilead Sciences faces risks and challenges that could impact its performance and prospects. One of the primary challenges for Gilead is the potential for generic competition. As patents on some of its key products expire, there is a risk of generic manufacturers entering the market with lower-priced alternatives. This can lead to pricing pressures and a decline in market share for Gilead's established therapies. The company must continue to innovate and develop new drugs to mitigate the impact of generic competition.

Another challenge is the evolving regulatory environment. Changes in healthcare policies, pricing regulations, and reimbursement systems can significantly impact the profitability of pharmaceutical companies. Gilead operates in multiple regions and must navigate various regulatory frameworks, which can introduce uncertainties and challenges to its business operations.

Additionally, Gilead faces intense competition from established pharmaceutical and smaller biotech firms. Rapid technological advancements and evolving treatment paradigms characterize the industry. Competitors may develop new therapies or gain regulatory approvals threatening Gilead's market share. The company must continue to invest in research and development to maintain its competitive edge.

Clinical trial failures and delays are also inherent risks in the biopharmaceutical industry. Despite rigorous research and development processes, there is always a possibility that promising drug candidates may fail to meet efficacy or safety requirements during clinical trials. These setbacks can result in significant financial losses and delays in product launches, impacting Gilead's revenue streams.

Additionally, Gilead faces the challenge of addressing changing treatment landscapes and shifting patient preferences. Medical advancements, scientific discoveries, and evolving disease patterns can alter the demand for specific therapies. Gilead must anticipate and adapt to these changes to ensure its products remain relevant and effective.

Risk management is crucial for Gilead Sciences to mitigate potential challenges. The company employs rigorous clinical trial protocols, invests in diverse therapeutic areas, and pursues strategic partnerships to diversify its product portfolio. Gilead's strong financial position allows it to navigate uncertainties and invest in research and development initiatives. Furthermore, the company monitors regulatory developments and engages with policymakers to shape favorable healthcare policies.

GILD Stock Price History

GILD Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 6/17 - 6/21 (GILD)
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally
Bitcoin’s Biggest Year Yet
2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.
Vials of liquid on a white table and the logo of Gilead Sciences
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its Phase 3 HIV prevention trial, marking the first trial showing zero infections.
Vials of liquid on a white table and the logo of Gilead Sciences
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial.
Bitcoin’s Biggest Year Yet
2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.
Gilead Sciences (NASDAQ:GILD) Stock Price Up 1.5%
Should You Hold Gilead Sciences (GILD)?
Gilead Records Positive Phase III Results In HIV
See More Headlines
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/25/2024
Ex-Dividend for 6/27 Dividend
6/14/2024
Dividend Payable
6/27/2024
Today
7/09/2024
Next Earnings (Confirmed)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GILD
CUSIP
37555810
Employees
18,000
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$84.00
High Stock Price Target
$105.00
Low Stock Price Target
$69.00
Potential Upside/Downside
+24.4%
Consensus Rating
Hold
Rating Score (0-4)
2.37
Research Coverage
19 Analysts

Profitability

Net Income
$5.67 billion
Pretax Margin
3.91%

Debt

Sales & Book Value

Annual Sales
$27.12 billion
Cash Flow
$9.07 per share
Book Value
$18.26 per share

Miscellaneous

Outstanding Shares
1,245,850,000
Free Float
1,242,240,000
Market Cap
$84.16 billion
Optionable
Optionable
Beta
0.18

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Daniel P. O'Day (Age 60)
    Chairman & CEO
    Comp: $6.99M
  • Mr. Andrew D. DickinsonMr. Andrew D. Dickinson (Age 54)
    Chief Financial Officer
    Comp: $2.66M
  • Ms. Deborah H. Telman (Age 59)
    Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
    Comp: $2.56M
  • Ms. Johanna MercierMs. Johanna Mercier (Age 54)
    Chief Commercial Officer
    Comp: $3.1M
  • Dr. Merdad V. Parsey M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $2.79M
  • Ms. Sandra Patterson (Age 57)
    Senior VP, Corporate Controller & Principal Accounting Officer
  • Ms. Jacquie Ross C.F.A.
    Vice President of Investor Relations
  • Ms. Jyoti K. Mehra (Age 48)
    Executive Vice President of Human Resources
  • Dr. Linda Slanec Higgins Ph.D. (Age 62)
    Senior Vice President of Research, Innovation & Portfolio
  • Dr. Rudolf Ertl (Age 78)
    Senior Vice President of Commercial Operations of Australia, Canada, Europe

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

  • Gilead Sciences reported a revenue of $6.69 billion for the quarter, surpassing the consensus estimate, indicating strong financial performance.
  • The company's dividend yield is 4.50%, offering investors a steady income stream through dividends.
  • Recent insider activity shows that an insider sold shares at an average price of $72.96, potentially signaling confidence in the company's future prospects.
  • Gilead Sciences has a diverse portfolio of medicines addressing unmet medical needs, providing stability and growth potential.
  • Despite recent fluctuations, Gilead Sciences has a market capitalization of $85.48 billion, indicating its position as a significant player in the biopharmaceutical industry.

Cons

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

  • Gilead Sciences' stock price has experienced volatility, trading at $68.61 on the latest trading day, potentially indicating uncertainty in the market.
  • The company's payout ratio is high at 855.56%, suggesting that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment for growth.
  • The PE ratio of 190.58 is considerably high, indicating that the stock may be overvalued compared to its earnings potential.
  • Gilead Sciences recently reported a negative EPS of ($1.32) for the quarter, which may raise concerns about the company's profitability in the short term.
  • The company's debt-to-equity ratio of 1.31 may pose risks in terms of financial leverage and interest obligations.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, July 2, 2024. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

GILD Stock Analysis - Frequently Asked Questions

How have GILD shares performed this year?

Gilead Sciences' stock was trading at $81.01 at the beginning of the year. Since then, GILD shares have decreased by 16.6% and is now trading at $67.55.
View the best growth stocks for 2024 here
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, April, 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences's quarterly revenue was up 5.3% compared to the same quarter last year.
Read the conference call transcript
.

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Gilead Sciences have any subsidiaries?

Gilead Sciences subsidiaries include MYR, Immunomedics, Forty Seven, Cell Design Labs, Kite Pharma, Nimbus Apollo, Epitherapeutics, and more.

Who are Gilead Sciences' major shareholders?

Top institutional shareholders of Gilead Sciences include Confluence Investment Management LLC (0.10%), DNB Asset Management AS (0.02%), Boston Common Asset Management LLC (0.01%) and First Financial Bank Trust Division (0.01%). Insiders that own company stock include Andrew D Dickinson, Merdad Parsey, Johanna Mercier, Diane E Wilfong and Brett A Pletcher.
View institutional ownership trends
.

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE) and Tesla (TSLA).

This page (NASDAQ:GILD) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners